The FDA has granted traditional approval to pembrolizumab for unresectable/metastatic TMB-H solid tumors.
News|Videos|July 26, 2024
Results From the Phase 1 Study of the Novel BCL2 Inhibitor Sonrotoclax in Combination with Zanubrutinib for Relapsed/Refractory CLL/SLL Show Deep and Durable Responses
Author(s)Stephen Opat, MBBS
BGB-11417-101 is a global phase 1/1b study evaluating sonrotoclax as monotherapy, or in combination ± zanubrutinib, and ± obinutuzumab in patients with B-cell malignancies. (NCT04277637)
Advertisement
Advertisement
Related to this article
The FDA granted fast track designation to SBE303 for locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin.
The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.
Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.
Two MD Anderson Cancer Center researchers were elected to the National Academy of Medicine for contributions to cancer care and research.
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
2
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
3
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
4
Dr Oberstein on the Rationale for Evaluating the PD-1/IL-15 Fusion Protein SAR445877 in MSS CRC
5